<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8258114</article-id><article-id pub-id-type="pmcid-ver">PMC8258114.1</article-id><article-id pub-id-type="pmcaid">8258114</article-id><article-id pub-id-type="pmcaiid">8258114</article-id><article-id pub-id-type="pmid">34239445</article-id><article-id pub-id-type="doi">10.3389/fphar.2021.698352</article-id><article-id pub-id-type="publisher-id">698352</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>A Review of Auraptene as an Anticancer Agent</article-title><alt-title alt-title-type="left-running-head">Tayarani-Najaran et al.</alt-title><alt-title alt-title-type="right-running-head">Auraptene as an Anticancer Agent</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tayarani-Najaran</surname><given-names initials="Z">Zahra</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tayarani-Najaran</surname><given-names initials="N">Nilufar</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eghbali</surname><given-names initials="S">Samira</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="corresp" rid="c001">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1312356/overview"/></contrib></contrib-group><aff id="aff1">
<label><sup>1</sup></label>Medical Toxicology Research Center, Mashhad University of Medical Sciences, <addr-line>Mashhad</addr-line>, <country>Iran</country>
</aff><aff id="aff2">
<label><sup>2</sup></label>Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, <addr-line>Mashhad</addr-line>, <country>Iran</country>
</aff><aff id="aff3">
<label><sup>3</sup></label>Department of Prosthodontics, School of Dentistry, Mashhad University of Medical Sciences, <addr-line>Mashhad</addr-line>, <country>Iran</country>
</aff><aff id="aff4">
<label><sup>4</sup></label>Department of Pharmacognosy, School of Pharmacy, Birjand University of Medical Sciences, <addr-line>Birjand</addr-line>, <country>Iran</country>
</aff><aff id="aff5">
<label><sup>5</sup></label>Cellular and Molecular Research Center, Birjand University of Medical Sciences, <addr-line>Birjand</addr-line>, <country>Iran</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/907847/overview">Halina Was</ext-link>, Military Institute of Medicine, Poland</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/342307/overview">Prashant Kaushik</ext-link>, University of Valencia, Spain</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1315898/overview">Omid Gholami</ext-link>, Sabzevar University of Medical Sciences, Iran</p></fn><corresp id="c001">*Correspondence: Samira Eghbali, <email>eghbalis98@gmail.com</email></corresp><fn fn-type="other"><p>This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>6</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">375280</issue-id><elocation-id>698352</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2021</year></date><date date-type="accepted"><day>09</day><month>6</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>06</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>07</day><month>07</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2021-07-09 15:16:30.777"><day>09</day><month>07</month><year>2021</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2021 Tayarani-Najaran, Tayarani-Najaran and Eghbali.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Tayarani-Najaran, Tayarani-Najaran and Eghbali</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-12-698352.pdf"/><abstract><p>Auraptene is a bioactive monoterpene coumarin isolated from <italic toggle="yes">Citrus aurantium</italic> and <italic toggle="yes">Aegle marmelos</italic> that belong to the Rutaceae family. Auraptene can modulate intracellular signaling pathways that control cell growth, inflammation and apoptosis and can exert pharmacological properties such as anti-bacterial, anti-fungal, antileishmania and anti-oxidant activity. Auraptene had inhibitory and chemo-preventive effects on the proliferation, tumorigenesis and growth of several cancer cell lines through increase in the activity of glutathione S-transferase, formation of DNA adducts and reduction of the number of aberrant crypt foci. Auraptene exhibits anticancer effects via targeting different cell signaling pathways such as cytokines, genes modulating cellular proliferation, growth factors, transcription factors and apoptosis. The present review is a detailed survey of scientific researches on the cytotoxicity and anticancer activity of Auraptene on cancer cells and tumor bearing animals.</p></abstract><kwd-group><kwd>Auraptene</kwd><kwd>Rutaceae</kwd><kwd>cytotoxicity</kwd><kwd>anticancer activity</kwd><kwd>cancer cells</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Mashhad University of Medical Sciences<named-content content-type="fundref-id">10.13039/501100004748</named-content></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Coumarins are a large class of natural compounds mainly found in the Apiaceae, Rutaceae, and Composita families. The three main groups of coumarins are: 1) ring-fused coumarins, 2) substituted coumarins and 3) C- and O-prenylcoumarins (<xref rid="B6" ref-type="bibr">Eghbaliferiz et al., 2020</xref>).</p><p>Auraptene, 7-geranyloxycoumarin, is a member of umbelliferone coumarins in which the phenolic hydrogen has been replaced by a geranyl group. Auraptene is isolated from many of the edible fruits and vegetables of the genus <italic toggle="yes">Ferula</italic> and <italic toggle="yes">Citrus</italic> like lemons, grapefruits and oranges. Auraptene indicates a variety of therapeutic properties such as antidiabetic, antiprotozoal, anti-bacterial, anti-fungal, anti-genotoxic, antileishmanial, anti-inflammatory, antihelicobacter, and immunomodulatory activities (<xref rid="B2" ref-type="bibr">Bibak et al., 2019</xref>). This compound showed significant effect on the treatment of several chronic illnesses including hypertension, nonalcoholic fatty liver and cystic fibrosis (<xref rid="B5" ref-type="bibr">Derosa et al., 2016</xref>; <xref ref-type="fig" rid="F1">Figure 1</xref>).</p><fig id="F1" position="float" orientation="portrait"><label>FIGURE 1</label><caption><p>Structure of auraptene.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-12-698352-g001.jpg"/></fig><p>Tumor is a group of cells/tissues due to the activation of various oncogenes or inactivation of tumor suppressors has lost its control on the normal growth at the gene level. Tumor tissue can be divided into malignant (cancerous) and benign (non-cancerous) according to the size and growth features. Malignant tumor grows rapidly and often infiltrate to the surrounding tissues without envelops on the surface. Patients with advanced cancer after surgical excision exhibited severe systemic symptoms and high recurrence rate, that causing a big challenge for cancer therapy. In view of the enormous damage caused by cancer, the development of new antitumor treatments has become a research hotspot. Natural products are a good source of antitumor compounds. In recent years, auraptene have drawn scientists&#8217; attention because of its broad-spectrum and effective antitumor activities (<xref rid="B9" ref-type="bibr">Fu et al., 2020</xref>).</p><p>The information and literature available in this review have been obtained through the Pubmed, Scopus, and Science Direct databases for English articles published until 2020. For this purpose, we used appropriate keywords including &#8220;auraptene&#8221; or &#8220;coumarin&#8221; and &#8220;cancer&#8221; or &#8220;cytotoxic.&#8221; The purpose of this review is to summarize the therapeutic effect and mechanism of auraptene in different types of cancers.</p></sec><sec id="s2"><title>Anticancer Properties of Auraptene</title><p>The cytotoxic, antitumor and anticancer activities of auraptene have been addressed in many <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> studies. The underling mechanisms have been discussed in the next paragraphs and summarized in <xref ref-type="fig" rid="F2">Figure 2</xref> and <xref rid="T1" ref-type="table">Table 1</xref> and <xref ref-type="fig" rid="F3">Figure 3</xref> displays the molecular mechanism of auraptene in cancer treatment.</p><fig id="F2" position="float" orientation="portrait"><label>FIGURE 2</label><caption><p>The inhibition effects of auraptene in different type of cancer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-12-698352-g002.jpg"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>TABLE 1</label><caption><p>The antitumor experiment of auraptene <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Type of cancer</th><th align="center" rowspan="1" colspan="1">Experimental model</th><th align="center" rowspan="1" colspan="1">Dose</th><th align="center" rowspan="1" colspan="1">IC<sub>50</sub>
</th><th align="center" rowspan="1" colspan="1">Mechanism</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">SW-620, MDA-MB-231, MCF-7</td><td align="center" rowspan="1" colspan="1">0.1&#8211;100&#160;&#181;M</td><td align="center" rowspan="1" colspan="1">4.18&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Modulation of ERs and suppression of acyl-CoA</td><td align="left" rowspan="1" colspan="1">
<xref rid="B4" ref-type="bibr">De Medina et al. (2010)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">MDA-MB-231, MCF-7 and rat</td><td align="center" rowspan="1" colspan="1">1&#8211;50&#160;&#181;M 200, 500&#160;ppm</td><td align="center" rowspan="1" colspan="1">85% inhibition</td><td align="left" rowspan="1" colspan="1">Inhibition of cyclin D1</td><td align="left" rowspan="1" colspan="1">
<xref rid="B25" ref-type="bibr">Krishnan et al. (2009)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">MCF-7</td><td align="center" rowspan="1" colspan="1">250&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">61.3&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Up-regulation of caspase-3 and caspase-8 and down-regulation of MMP9, MMP2, VEGFR-1, and VEGFR-2</td><td align="left" rowspan="1" colspan="1">
<xref rid="B3" ref-type="bibr">Charmforoshan et al. (2019)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">MCF-7</td><td align="center" rowspan="1" colspan="1">10, 20, 40&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">17.26&#8211;29.66&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Down-regulation of Mcl-1 mRNA</td><td align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Motlagh and Gholami (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">MCF-7 cells</td><td align="center" rowspan="1" colspan="1">500&#160;ppm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reduction of cyclin D1 protein expression and inhibition of IGF-1</td><td align="left" rowspan="1" colspan="1">
<xref rid="B24" ref-type="bibr">Krishnan and Kleiner-Hancock (2012)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">MGC-803 cells</td><td align="center" rowspan="1" colspan="1">0&#8211;4&#160;&#181;M</td><td align="center" rowspan="1" colspan="1">0.78&#8211;10.78&#160;&#181;M</td><td align="left" rowspan="1" colspan="1">Expression of apoptosis- related protein</td><td align="left" rowspan="1" colspan="1">
<xref rid="B28" ref-type="bibr">Li et al. (2018)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td align="center" rowspan="1" colspan="1">100, 500&#160;ppm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of CD74 production</td><td align="left" rowspan="1" colspan="1">
<xref rid="B41" ref-type="bibr">Sekiguchi et al. (2012)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">NCI-N87 cells</td><td align="center" rowspan="1" colspan="1">20&#160;&#181;M</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reduction of ERK 1/2 activation and IL-8 production</td><td align="left" rowspan="1" colspan="1">
<xref rid="B40" ref-type="bibr">Sekiguchi et al. (2010)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="left" rowspan="1" colspan="1">SNU-1 cells</td><td align="center" rowspan="1" colspan="1">25&#8211;200&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">&#8804;25&#160;&#181;M</td><td align="left" rowspan="1" colspan="1">Inhibition of mTOR, activation of p53 and increase in the phosphorylation of Akt</td><td align="left" rowspan="1" colspan="1">
<xref rid="B30" ref-type="bibr">Moon et al. (2015)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">HT-29 and HT-116 cells</td><td align="center" rowspan="1" colspan="1">10&#160;&#181;M</td><td align="center" rowspan="1" colspan="1">&#8805;50%</td><td align="left" rowspan="1" colspan="1">Suppression of CD166 and CD44 and inhibition of colonospheres</td><td align="left" rowspan="1" colspan="1">
<xref rid="B8" ref-type="bibr">Epifano et al. (2013)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">F344 rats</td><td align="center" rowspan="1" colspan="1">100, 500&#160;ppm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Activation of the phase II enzymes QR and GST</td><td align="left" rowspan="1" colspan="1">
<xref rid="B43" ref-type="bibr">Tanaka et al. (1998a)</xref>; <xref rid="B46" ref-type="bibr">Tanaka et al. (1997)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">C57BL/KsJ-db/db mice</td><td align="center" rowspan="1" colspan="1">10&#160;mg/kg</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of COX-2 and iNOS, reduction of cell proliferation and lipid profiles</td><td align="left" rowspan="1" colspan="1">
<xref rid="B12" ref-type="bibr">Hayashi et al. (2007)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">C57BL/KsJ-db/db mice</td><td align="center" rowspan="1" colspan="1">10&#160;mg/kg</td><td align="center" rowspan="1" colspan="1">67&#8211;80% inhibition</td><td align="left" rowspan="1" colspan="1">Reduction of triglycerides and anti-inflammatory activity of auraptene</td><td align="left" rowspan="1" colspan="1">
<xref rid="B48" ref-type="bibr">Tanaka et al. (2008)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">CD-1 (ICR) mice</td><td align="center" rowspan="1" colspan="1">100, 500&#160;ppm</td><td align="center" rowspan="1" colspan="1">63&#8211;83% inhibition</td><td align="left" rowspan="1" colspan="1">Suppression of colonic inflammation and modulation of proinflammatory cytokines</td><td align="left" rowspan="1" colspan="1">
<xref rid="B45" ref-type="bibr">Tanaka et al. (2010)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">HT-29 cell line</td><td align="center" rowspan="1" colspan="1">1&#8211;50&#160;&#181;M</td><td align="center" rowspan="1" colspan="1">2.8 and 3&#160;&#181;M</td><td align="left" rowspan="1" colspan="1">Suppression of proMMP-7 and inhibition of ERK1/2</td><td align="left" rowspan="1" colspan="1">
<xref rid="B19" ref-type="bibr">Kawabata et al. (2006b)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">ICR mice</td><td align="center" rowspan="1" colspan="1">100, 500&#160;ppm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reduction of COX-2, PCNA, iNOS</td><td align="left" rowspan="1" colspan="1">
<xref rid="B23" ref-type="bibr">Kohno et al. (2006)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">Colonic mucosa mouse</td><td align="center" rowspan="1" colspan="1">0.1% w/w</td><td align="center" rowspan="1" colspan="1">82% inhibition</td><td align="left" rowspan="1" colspan="1">Inhibition of MMP-2, MMp-9 and suppression DSS</td><td align="left" rowspan="1" colspan="1">
<xref rid="B18" ref-type="bibr">Kawabata et al. (2006a)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">HT29 cells</td><td align="center" rowspan="1" colspan="1">10, 20&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">39&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Reduction of hyperthermia and down-regulation of HSP27</td><td align="left" rowspan="1" colspan="1">
<xref rid="B32" ref-type="bibr">Moussavi et al. (2018)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon cancer</td><td align="left" rowspan="1" colspan="1">HT29 cells</td><td align="center" rowspan="1" colspan="1">10, 20, 40, and 80&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">31.8&#8211;42.1%</td><td align="left" rowspan="1" colspan="1">Down regulation of CD44, ALDH1 and inhibited expression of GATA6</td><td align="left" rowspan="1" colspan="1">
<xref rid="B33" ref-type="bibr">Moussavi et al. (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic cancer</td><td align="left" rowspan="1" colspan="1">F344 rats</td><td align="center" rowspan="1" colspan="1">100, 500&#160;ppm</td><td align="center" rowspan="1" colspan="1">83% inhibition</td><td align="left" rowspan="1" colspan="1">Reduction of GST, TGF-&#945;</td><td align="left" rowspan="1" colspan="1">
<xref rid="B38" ref-type="bibr">Sakata et al. (2004)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic cancer</td><td align="left" rowspan="1" colspan="1">F344 rats</td><td align="center" rowspan="1" colspan="1">100, 500&#160;ppm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#946;-catenin mutation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B11" ref-type="bibr">Hara et al. (2005)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic cancer</td><td align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td align="center" rowspan="1" colspan="1">30&#160;mg/kg</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Reduction of toxic bile acids, inhibition of inflammation and HSCs activation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B10" ref-type="bibr">Gao et al. (2018)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic cancer</td><td align="left" rowspan="1" colspan="1">Rat</td><td align="center" rowspan="1" colspan="1">500&#160;ppm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Nob induction of cell cycle inhibition and apoptosis</td><td align="left" rowspan="1" colspan="1">
<xref rid="B36" ref-type="bibr">Ohnishi et al. (2004)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatic cancer</td><td align="left" rowspan="1" colspan="1">RCC4 cell line</td><td align="center" rowspan="1" colspan="1">0&#8211;100&#160;&#956;M</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition the mitochondrial respiration and blockade HIF-1&#945;</td><td align="left" rowspan="1" colspan="1">
<xref rid="B15" ref-type="bibr">Jang et al. (2015)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">PC3 and DU145</td><td align="center" rowspan="1" colspan="1">30, 60&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">30&#8211;45%</td><td align="left" rowspan="1" colspan="1">Activation of caspase-9/3, Bax, inhibition of Bcl-2 and Mcl-1, increase the TUNEL-positive cells</td><td align="left" rowspan="1" colspan="1">
<xref rid="B27" ref-type="bibr">Lee et al. (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">PC3 and DU145</td><td align="center" rowspan="1" colspan="1">500&#160;ppm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Induction of apoptosis and cell cycle arrest</td><td align="left" rowspan="1" colspan="1">
<xref rid="B49" ref-type="bibr">Tang et al. (2007)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin cancer</td><td align="left" rowspan="1" colspan="1">ICR mouse skin</td><td align="center" rowspan="1" colspan="1">18&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">450&#160;&#956;M</td><td align="left" rowspan="1" colspan="1">Inhibition of TPA and suppression of O<sub>2</sub>
<sup>&#8722;</sup>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B34" ref-type="bibr">Murakami et al. (1997)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin cancer</td><td align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td align="center" rowspan="1" colspan="1">500, 1,000&#160;mg/kg</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Induction of apoptosis, inhibition of metastasis of B16BL6 melanoma cells</td><td align="left" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Tanaka et al. (2000)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin cancer</td><td align="left" rowspan="1" colspan="1">Xenograft mouse</td><td align="center" rowspan="1" colspan="1">200&#160;mg/kg</td><td align="center" rowspan="1" colspan="1">84% inhibition</td><td align="left" rowspan="1" colspan="1">Suppression of LPS-induced NF-&#954;B activation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B21" ref-type="bibr">Kleiner-Hancock et al. (2010)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin cancer</td><td align="left" rowspan="1" colspan="1">M4Beu melanoma</td><td align="center" rowspan="1" colspan="1">10&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">17.1&#160;&#181;M</td><td align="left" rowspan="1" colspan="1">Induction of caspase-dependent apoptosis and cell-cycle arrest</td><td align="left" rowspan="1" colspan="1">
<xref rid="B1" ref-type="bibr">Barthomeuf et al. (2008)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ovarian cancer</td><td align="left" rowspan="1" colspan="1">Hela cell line</td><td align="center" rowspan="1" colspan="1">10, 20, 40&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">13.33&#8211;13.87&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Down-regulation of MCl-1 gene expression</td><td align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Motlagh and Gholami (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ovarian cancer</td><td align="left" rowspan="1" colspan="1">Hela and A2780 cell line</td><td align="center" rowspan="1" colspan="1">12.5&#8211;100&#160;&#956;M</td><td align="center" rowspan="1" colspan="1">31.49 and 47.93&#160;&#956;M</td><td align="left" rowspan="1" colspan="1">Reduction of MMP-2 and MMP-9 enzymatic activity</td><td align="left" rowspan="1" colspan="1">
<xref rid="B14" ref-type="bibr">Jamialahmadi et al. (2018)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Esophageal cancer</td><td align="left" rowspan="1" colspan="1">KYSE30 cells</td><td align="center" rowspan="1" colspan="1">20&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">76&#8211;80&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Reduction expression of CD44, BMI-1</td><td align="left" rowspan="1" colspan="1">
<xref rid="B37" ref-type="bibr">Saboor-Maleki et al. (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Esophageal cancer</td><td align="left" rowspan="1" colspan="1">KYSE30 cells</td><td align="center" rowspan="1" colspan="1">10, 20, 40&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">11.75&#8211;15.25&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Down-regulation of Mcl-1 gene expression</td><td align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Motlagh and Gholami (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Leukaemia</td><td align="left" rowspan="1" colspan="1">Jurkat cells</td><td align="center" rowspan="1" colspan="1">20&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">16.5&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Activation of caspase cascade, caspase-8 and caspase-3, degradation of PARP and suppression of Bcl-xL</td><td align="left" rowspan="1" colspan="1">
<xref rid="B16" ref-type="bibr">Jun et al. (2007)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Leukaemia</td><td align="left" rowspan="1" colspan="1">Jurkat cells</td><td align="center" rowspan="1" colspan="1">10, 20, 40&#160;&#956;g/ml</td><td align="center" rowspan="1" colspan="1">11.3&#8211;11.49&#160;&#956;g/ml</td><td align="left" rowspan="1" colspan="1">Down-regulated Mcl-1 mRNA expression</td><td align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Motlagh and Gholami (2017)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral carcinogenesis</td><td align="left" rowspan="1" colspan="1">F344 rats</td><td align="center" rowspan="1" colspan="1">100, 500&#160;ppm</td><td align="center" rowspan="1" colspan="1">63&#8211;91% reduction</td><td align="left" rowspan="1" colspan="1">Suppression of 4-NQO activity, decreased dysplastic lesions, inhibited the expression of cell proliferation</td><td align="left" rowspan="1" colspan="1">
<xref rid="B47" ref-type="bibr">Tanaka et al. (1998b)</xref>
</td></tr></tbody></table></table-wrap><fig id="F3" position="float" orientation="portrait"><label>FIGURE 3</label><caption><p>The antitumor mechanism of auraptene.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-12-698352-g003.jpg"/></fig><sec id="s2-1"><title>Breast Cancer</title><p>Breast cancer is the most widespread and second leading cause of death in the female adult population. Hormone positive and negative Breast cancer may be treated according to the hormone status of the cancer cells. Hormone suppressive treatment is assigned to hormone sensitive cells (<xref rid="B7" ref-type="bibr">EghbaliFeriz et al., 2018</xref>).</p><p>Auraptene, a prenyloxycoumarin from <italic toggle="yes">Citrus</italic> species, demonstrated anticancer activity against breast cancer. The underlying mechanism responsible for this effect is the modulation of estrogen receptors (ERs) and suppression of cholesterol acyl transferase (ACAT) (<xref rid="B4" ref-type="bibr">De Medina et al., 2010</xref>). Auraptene inhibited the proliferation of MDA-MB-231 and MCF-7 human breast cancer cells and significantly inhibited cyclin D1 dose-dependently and delayed tumor progression in rat mammary tumors (<xref rid="B25" ref-type="bibr">Krishnan et al., 2009</xref>). It has also been reported that the dietary administration of auraptene delayed tumor expansion (or extension). Auraptene reduced cyclin D1 protein expression and inhibition of insulin-like growth factor-1(IGF-1) in MCF-7 cells (<xref rid="B24" ref-type="bibr">Krishnan and Kleiner-Hancock, 2012</xref>). In another study, auraptene from <italic toggle="yes">Ferula szowitsiana</italic> root indicated anti-tumor activity in human breast cancer cells via up-regulation of caspase-3 and caspase-8 and down-regulation of MMP-9, MMP-2, VEGFR-1 (vascular endothelial growth factor), and VEGFR-2 genes (<xref rid="B3" ref-type="bibr">Charmforoshan et al., 2019</xref>). Motlagh et al. investigated the cytotoxic effects of umbelliprenin and auraptene against MCF-7 cell lines. Auraptene was more cytotoxic than umbelliprenin and exerted this effect through down-regulation of Myeloid Cell Leukaemia Type-1 (Mcl-1) mRNA expression (<xref rid="B31" ref-type="bibr">Motlagh and Gholami, 2017</xref>).</p></sec><sec id="s2-2"><title>Colorectal Cancer</title><p>Colorectal cancer is one of the most prevalent and third leading cause of death among patients in the world. The best strategy for treatment of colorectal cancer is surgical resection combined with chemotherapy and radiation (<xref rid="B17" ref-type="bibr">Kaur and Kaur, 2015</xref>).</p><p>Auraptene at a concentration of 10&#160;&#181;M significantly inhibited the growth and formation of HT-29 and HT-116 cells <italic toggle="yes">in vitro</italic>. Auraptene was reported to suppress the expression of CD166 and CD44 in chemo-resistant HT-29 cells and inhibit the formation of colonospheres and growth of both chemo-resistant and wild-type colon cancer cells (<xref rid="B8" ref-type="bibr">Epifano et al., 2013</xref>). The administration of auraptene significantly inhibited the development of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) in male F344 rats. The mechanisms responsible for this effect were activation of the phase II enzymes QR (quinone reductase) and GST (glutathione Stransferase), reduction of lipid peroxidation and suppression of cell proliferation biomarkers such as ornithine decarboxylase activity, 5-bromo-29-deoxyuridine labeling-index and polyamine content in the colonic mucosa (<xref rid="B46" ref-type="bibr">Tanaka et al., 1997</xref>; <xref rid="B43" ref-type="bibr">Tanaka et al., 1998a</xref>). In another study, administration of auraptene (10&#160;mg/kg) significantly inhibited the incidence of colon carcinogenesis in C57BL/KsJ-db/db mice. The inhibition of COX-2 and iNOS in colonic epithelial cells, reduction of cell proliferation, lipid profiles and induction of apoptosis was responsible for this effect (<xref rid="B12" ref-type="bibr">Hayashi et al., 2007</xref>). Also, the incidence and multiplicity of colonic adenocarcinomas is suppressed by administration of collinin and auraptene at dose of 0.05 and 0.01%, respectively in clitis- and obesity-related colon tumorigenesis models in C57BL/KsJ-db/db mice. This activity attributed to anti-inflammatory activity of auraptene and collinin (<xref rid="B48" ref-type="bibr">Tanaka et al., 2008</xref>). Auraptene has been reported to prevent the proliferation of colorectal cancer by modulation of inflammatory and expression of proinflammatory cytokines in CD-1 (ICR) mice. These results indicate that the administration of auraptene suppresses the colonic inflammation and modulates proinflammatory cytokines including interleukin (IL)-6 and IL-1b, tumor necrosis factor-a, nuclear factor-kappaB, Stat3 and NF-E2-related factor 2 in adenocarcinomas (<xref rid="B45" ref-type="bibr">Tanaka et al., 2010</xref>). In a study conducted by Kawabata et al., auraptene suppressed the growth of human colorectal adenocarcinoma HT-29 cell line. The suppression of proMMP-7 (Matrix metalloproteinase) production and inhibition of extracellular signal-regulated kinase (ERK1/2) protein translation responsible for this effect (<xref rid="B19" ref-type="bibr">Kawabata et al., 2006b</xref>).</p><p>Kohno et al. reported that auraptene significantly reduced the rates of cyclooxygenase (COX)-2, proliferating cell nuclear antigen (PCNA), nitrotyrosine and inducible nitric oxide (iNOS) in adenocarcinomas. Also, auraptene increased the apoptotis and suppressed the occurrence of colonic adenocarcinoma in male ICR mice (<xref rid="B23" ref-type="bibr">Kohno et al., 2006</xref>). It addition, auraptene inhibited MMP-2, MMP-9 expression in HT-29 human colon cancer cells suggesting the anti-metastatic activity of auraptene (<xref rid="B18" ref-type="bibr">Kawabata et al., 2006a</xref>). In another study, auraptene reduced the toxicity of hyperthermia in human colon adenocarcinoma HT29 cells as a new and important therapeutic strategy usually used as an adjunct to cancer treatment, which was verified by down-regulation of HSP27 (<xref rid="B32" ref-type="bibr">Moussavi et al., 2018</xref>). Jalilzadeh et al. reported that nano-encapsulated formulations with biodegradable penta-block PLA-PCL-PEG-PCL-PLA and triblock PCL-PEG-PCL increase the bio-distribution, solubility and delivery of aurapetne to targeted sites and improve the anticancer activity of auraptene especially in colon cancer cells (<xref rid="B13" ref-type="bibr">Jalilzadeh et al., 2020</xref>). In colon adenocarcinoma cells, synergism between auraptene and ionizing radiation increased the efficacy of treatment on HT29 cells. Auraptene down regulated CD44, ALDH1 (aldehyde dehydrogenase 1) and inhibited the expression of GATA6 (GATA binding protein 6) (<xref rid="B33" ref-type="bibr">Moussavi et al., 2017</xref>). Coadministration of auraptene and radiotherapy for treatment of colon carcinoma cells was investigated <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo.</italic> Increase in radiotherapy effects by AUR was observed and confirmed by increased number of apoptotic cells. <italic toggle="yes">In vivo</italic>, after administration of AUR + radiotherapy significant regression in tumor size, down regulation of Cyclin D1 and CD44, involvement of PI3K-AKT-mTORC signaling pathway and Caspase-3 was observed (<xref rid="B39" ref-type="bibr">Salari et al., 2020</xref>).</p></sec><sec id="s2-3"><title>Gastric Cancer</title><p>The one of the most common malignancies and third leading cause of death worldwide is gastric cancer. The main therapeutic approach for the treatment of gastric cancer is chemotherapy (<xref rid="B50" ref-type="bibr">Torre et al., 2015</xref>).</p><p>The major human pathogen that plays an important role in gastric cancer and chronic gastritis is <italic toggle="yes">Helicobacter pylori</italic>. Auraptene inhibited <italic toggle="yes">Helicobacter pylori</italic> and CD74 production by reduction of extracellular signaling-regulated kinase (ERK) 1/2 activation and IL-8 production in NCI-N87 gasteric carcinoma cells (<xref rid="B40" ref-type="bibr">Sekiguchi et al., 2010</xref>). It has also been reported that auraptene suppresses <italic toggle="yes">Helicobacter pylori</italic> adhesion. The mechanism attributed to this activity was inhibition of CD74 production and reduction of inflammatory cytokine expression such as tumor necrosis factor-&#945; and interleukin-1&#946; in C57BL/6 mice (<xref rid="B41" ref-type="bibr">Sekiguchi et al., 2012</xref>). In another study auraptene, indicated anticancer effect against SNU-1 gastric cancer cells. The underlying mechanism was induction of apoptosis and cell cycle arrest by inhibition of mTOR signaling pathway and activation of p53 along with increase in the phosphorylation of Akt (<xref rid="B30" ref-type="bibr">Moon et al., 2015</xref>). Li et al. reported that four new terpene coumarins with notable changes in the skeletal backbone from 2-Z auraptene, a synthesized monoterpene coumarin, demonstrate antiproliferative activity against human gastric cancer cells (MGC-803) with IC<sub>50</sub> values of 0.78 &#177; 0.13&#8211;10.78 &#177; 1.83&#160;&#181;M and induce apoptosis (<xref rid="B28" ref-type="bibr">Li et al., 2018</xref>).</p></sec><sec id="s2-4"><title>Hepatic Cancer</title><p>As one of the most common types of liver cancer, Hepatocellular carcinoma (HCC) is seen most often in people suffering from chronic liver diseases such as hepatitis B or hepatitis C virus infected individuals. Plant based natural products are routinely used as adjuvants to chemotherapeutics (<xref rid="B52" ref-type="bibr">Yang et al., 2019</xref>).</p><p>Auraptene was introduced as a powerful chemopreventive agent against N,N-diethylnitrosamine (DEN) that initiated hepatocarcinogenesis in male F344 rats. In one study, the consumption of AUR at doses of 100 and 500&#160;ppm during DEN exposure reduced the numbers of glutathione S-transferase (GST) and transforming growth factor (TGF)-&#945; and also suppressed the incidence of liver cell carcinoma (<xref rid="B38" ref-type="bibr">Sakata et al., 2004</xref>). It has also been reported that daily consumption of auraptene during DEN exposure inhibited hepatocellular carcinoma <italic toggle="yes">via</italic> &#946;-catenin mutation in male F344 rats (<xref rid="B11" ref-type="bibr">Hara et al., 2005</xref>). Gao et al. investigated the hepatoprotection of auraptene against thioacetamide (TAA)-induced hepatic fibrosis in mice. The underlying mechanism was reduction of toxic bile acids, inhibition of inflammation, and activation of hepatic stellate cells (HSCs), all of which were related to the activation of farnesoid X receptor (FXR) (<xref rid="B10" ref-type="bibr">Gao et al., 2018</xref>). It seems inhibition of HCC cell growth and cell cycle arrest are not the mechanisms of action of auraptene in hepatocellular carcinoma of rat when compared with nobiletin (<xref rid="B36" ref-type="bibr">Ohnishi et al., 2004</xref>). In another study which investigated F344 rats, similar data was obtained and auraptene did not inhibit cell proliferation (<xref rid="B20" ref-type="bibr">Kitano et al., 2000</xref>).</p><p>Hypoxia-inducible factor 1&#945; (HIF-1&#945;) is an important regulator of cancer metabolism, angiogenesis and migration which is produced in renal cell carcinoma (RCC). Jang et al., reported auraptene suppresses the progression of RCC through inhibition of mitochondrial respiration and blockade of HIF-1&#945; signaling, without any cytotoxic effects (<xref rid="B15" ref-type="bibr">Jang et al., 2015</xref>).</p></sec><sec id="s2-5"><title>Prostate Cancer</title><p>As the main leading cause of death among men, prostate cancer is routinely treated with chemotherapy, hormonal therapy and radiotherapy. Some natural products have shown promising effects as adjuvant treatments for prostate cancer (<xref rid="B27" ref-type="bibr">Lee et al., 2017</xref>).</p><p>Lee et al. investigated the anticancer mechanism of auraptene in PC3 and DU145 prostate cancer cells. Auraptene induces apoptosis in prostate cancer cells through activation of caspase-9/3 and Bax, inhibition of Bcl-2 and myeloid cell leukemia 1 (Mcl-1), increases in the number of transferase dUTP nick end labeling (TUNEL)-positive cells and sub-G1 population, and regulation of apoptosis-related proteins such as poly (ADP-ribose) polymerase (PARP) (<xref rid="B27" ref-type="bibr">Lee et al., 2017</xref>). In another study, the growth of androgen positive DU145 and PC3 human prostate cancer cells was inhibited by both nobiletin and auraptene in a dose-dependent manner via induction of apoptosis and cell cycle arrest (<xref rid="B49" ref-type="bibr">Tang et al., 2007</xref>).</p></sec><sec id="s2-6"><title>Skin Cancer</title><p>Melanoma and nonmelanoma are two main classes of skin cancer with high and increasing incidence in the world. Surgery freezing (cryotherapy), anti-cancer creams, radiotherapy and a form of light treatment called photodynamic therapy (PDT) are therapeutic choices for skin cancer (<xref rid="B42" ref-type="bibr">Taleghani et al., 2021</xref>).</p><p>In ICR mouse skin, auraptene suppressed the skin tumorgenesis through inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA) and suppression of superoxide (O<sub>2</sub>
<sup>&#8722;</sup>) and intracellular hydroperoxide production in leukocytes (<xref rid="B34" ref-type="bibr">Murakami et al., 1997</xref>). In another study, auraptene and 1,4-phenylenebis (methylene) selenocyanate (p-XSC) suppressed the metastasis of melanoma cells to lung in mice. The underlying mechanism was induction of apoptosis and inhibition of metastasis of B16BL6 melanoma cells to lung (<xref rid="B44" ref-type="bibr">Tanaka et al., 2000</xref>). In human squamous cell carcinoma (SCC) xenografts, auraptene increased the protective effect of all-trans retinoic acid (ATRA) against human skin cancer cell growth in female SCID/bg mice and suppressed the LPS-induced NF-&#954;B activation (<xref rid="B21" ref-type="bibr">Kleiner-Hancock et al., 2010</xref>). Barthomeuf et al. reported that auraptene inhibits the growth of human M4Beu melanoma cells (IC<sub>50</sub> 17.1&#160;&#181;M) via induction of caspase-dependent apoptosis and cell-cycle arrest in G1 (<xref rid="B1" ref-type="bibr">Barthomeuf et al., 2008</xref>).</p></sec><sec id="s2-7"><title>Ovarian Cancer</title><p>Cervical and ovarian cancers are among the most common gynecologic cancers. Surgery, chemotherapy, and radiation are among the treatment plans (<xref rid="B22" ref-type="bibr">Koh et al., 2015</xref>). Like other cancers, herbs and phytocompounds are being progressively introduced as efficient complementary treatments for gynecologic cancers.</p><p>Between umbelliprenin and auraptene, auraptene showed more cytotoxic effects against Hela cancer cells <italic toggle="yes">via</italic> down-regulation of MCl-1 gene expression (<xref rid="B31" ref-type="bibr">Motlagh and Gholami, 2017</xref>). Auraptene has been reported to decrease the viability of human cervical and ovarian cancer cells and suppresses the migration and invasion of Hela and A2780 cell line by reduction of matrix metalloproteinase-2 (MMP-2) and metalloproteinase-9 (MMP-9) enzymatic activity, respectively (<xref rid="B14" ref-type="bibr">Jamialahmadi et al., 2018</xref>). Maleki et al. reported that prenylation at position six of the coumarin ring significantly improved the anticancer activity of aurapten. In this study, eight coumarins were examined and among them umbelliprenin, auraptene, umbelliferone and herniarin with prenylation substitution at position six indicated the best anticancer activity, especially against cervical cancer, with minimal cytotoxicity on normal cells (<xref rid="B29" ref-type="bibr">Maleki et al., 2020</xref>).</p></sec><sec id="s2-8"><title>Esophageal Cancer</title><p>Esophageal cancer is the seventh common cancer in humans. In a study conducted by Saboor-Maleki et al., auraptene upregulated P53 and P21 and downregulated the expression of stem-like cancer cell markers such as CD44 (cluster of differentiation 44), BMI-1 (B cell-specific moloney murine leukemia virus integration site 1) and increased the sensitivity of esophageal squamous cell carcinoma (ESCC) to paclitaxel, cisplatin, and 5-fluorouracil (<xref rid="B37" ref-type="bibr">Saboor-Maleki et al., 2017</xref>). In another study on esophageal carcinoma cell line (KYSE-30), auraptene down-regulated the MCl-1 gene expression and indicated more cytotoxic effect in comparison with umbelliprenin (<xref rid="B31" ref-type="bibr">Motlagh and Gholami, 2017</xref>).</p></sec><sec id="s2-9"><title>Other Cancer</title><p>Jun et al., showed that auraptene, from leaves of <italic toggle="yes">Z. schinifolium,</italic> on Jurkat T cells induce apoptosis through activation of caspase cascade (caspase-8 and caspase-3), degradation of PARP and suppression of Bcl-xL (<xref rid="B16" ref-type="bibr">Jun et al., 2007</xref>). In comparison between cytotoxic effects of auraptene and umbelliprenin on Jurkat cells, auraptene was more cytotoxic than umbelliprenin and down-regulated Mcl-1 mRNA expression (<xref rid="B31" ref-type="bibr">Motlagh and Gholami, 2017</xref>).</p><p>In male F344 rats, dietary administration of auraptene suppressed the carcinogenic activity of 4-nitroquinoline 1-oxide (4-NQO) and inhibited development of oral neoplasms, increased the activity of gluthathione S-transferase (GST) and quinone reductase (QR) in the tongue and liver and decreased dysplastic lesions (<xref rid="B47" ref-type="bibr">Tanaka et al., 1998b</xref>).</p></sec></sec><sec id="s3"><title>Pharmacokinetics of Auraptene</title><p>The pharmacokinetics of auraptene has been evaluated in several studies. Ye et al. determined the pharmacokinetics of auraptene in rat plasma using LC-MS/MS method. Data showed that a dose range of 0.5&#8211;200&#160;ng/ml of auraptene was safe and bioavailability of oral administration of auraptene was merely 8.5% in rats (<xref rid="B53" ref-type="bibr">Ye et al., 2016</xref>). In another study, the absorption and metabolism of auraptene in rodent models was examined. The result indicated that oral administration of AUR at 50&#8211;200&#160;mg/kg body wt induced glutathione S-transferase (GST) activity and xenobiotic phase II enzymes, and indicated chemopreventive effects in rodents. These effects increase, absorption and stable (stabilize) localization in the colon and liver (<xref rid="B35" ref-type="bibr">Murakami et al., 2000</xref>). Auraptene showed higher absorption rate in comparison with 7-ethoxycoumarin, with longer life span due to the presence of the geranyloxyl side chain (<xref rid="B26" ref-type="bibr">Kuki et al., 2008</xref>).</p></sec><sec id="s4"><title>Toxicology</title><p>The acute toxicity of orally administrated auraptene in rats was investigated and different concentrations of the compound (125&#8211;2,000&#160;mg/kg body weight) had no effect on mortality. However, administration of auraptene demonstrated some differences in ALP, ALT, AST, blood urea, total bilirubin, total protein, haematocrit, hemoglobin, RBC count, platelet count and MCHC (mean corpuscular haemoglobin concentration) in AUR-treated animals as compared to the controls but all were in normal reference ranges. Histopathological examination of organs such as liver, kidneys, bone marrow, heart and lungs indicated no toxic effects of auraptene and showed the safety of the compound (<xref rid="B51" ref-type="bibr">Vakili et al., 2017</xref>).</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>This review evaluated the effects of auraptene on different cancer cells both <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic>. Auraptene had inhibitory and chemo-preventive effects on the proliferation, tumorigenesis and growth of several cancer cell lines through increase in the activity of glutathione S-transferase, formation of DNA adducts and reduction of the number of aberrant crypt foci. Auraptene exhibits anticancer effects via targeting different cell signaling pathways such as cytokines, genes modulating cellular proliferation, growth factors, transcription factors and apoptosis.</p><p>Modulation of Bcl-2, increase in amount of Bax protein, reduction of MMP-2 and MMP-9, inhibition of NF-&#954;B, activation of caspase and p53-independent, suppression of superoxide (O<sub>2</sub>
<sup>&#8722;</sup>), down-regulation of Mcl-1 mRNA expression and reduction of mitochondrial membrane potential are important mechanisms for the cytotoxic and anticancer effects of auraptene. Low cytotoxic IC<sub>50</sub>s values of auraptene demonstrated its potency as a worthy phytochemical for cancer treatment. However, lack of clinical evaluation has made it difficult to use auraptene in conventional chemotherapeutic regimens for cancer treatment.</p><p>In conclusion, auraptene has an excellent safety profile and the ability to affect multiple molecular targets which are important in the prevention and/or management of a number of cancers. However, further studies and more clinical trials are needed to fully elucidate the putative potential of auraptene as an effective anticancer agent.</p></sec></body><back><ack><p>The authors wish to thanks Birjand and Mashhad University of Medical Sciences.</p></ack><sec id="s6"><title>Author Contributions</title><p>SE: Data curation, search for data, Writing&#8211;original draft, made the graphical figures, prepare the draft. ZT-N: Conceptualization, Data curation, search for data, Writing&#8211;review and editing, spelling editing. NT-N: Writing&#8211;review and editing and spelling editing.</p></sec><sec id="s7"><title>Funding</title><p>This work was supported by Research affair of Birjand and Mashhad University of medical Sciences.</p></sec><sec sec-type="COI-statement" id="s8"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barthomeuf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chollet</surname><given-names>P.</given-names></name></person-group> (<year>2008</year>). <article-title>Umbelliprenin from Ferula Szowitsiana Inhibits the Growth of Human M4Beu Metastatic Pigmented Malignant Melanoma Cells through Cell-Cycle Arrest in G1 and Induction of Caspase-dependent Apoptosis</article-title>. <source>Phytomedicine</source><volume>15</volume> (<issue>1-2</issue>), <fpage>103</fpage>&#8211;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2007.04.001</pub-id><pub-id pub-id-type="pmid">17689942</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bibak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shakeri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Keshavarzi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sathyapalan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>A Review of the Pharmacological and Therapeutic Effects of Auraptene</article-title>. <source>BioFactors</source><volume>45</volume> (<issue>6</issue>), <fpage>867</fpage>&#8211;<lpage>879</lpage>. <pub-id pub-id-type="doi">10.1002/biof.1550</pub-id><pub-id pub-id-type="pmid">31424600</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charmforoshan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oskoueian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Es-Haghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Inhibition of Human Breast Cancer Cells (MCF-7 Cell Line) Growth via Cell Proliferation, Migration, and Angiogenesis by Auraptene of Ferula Szowitsiana Root Extract</article-title>. <source>Food Measure</source><volume>13</volume> (<issue>4</issue>), <fpage>2644</fpage>&#8211;<lpage>2653</lpage>. <pub-id pub-id-type="doi">10.1007/s11694-019-00185-6</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Medina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Genovese</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paillasse</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Mazaheri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caze-Subra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bystricky</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Auraptene Is an Inhibitor of Cholesterol Esterification and a Modulator of Estrogen Receptors</article-title>. <source>Mol. Pharmacol.</source><volume>78</volume> (<issue>5</issue>), <fpage>827</fpage>&#8211;<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1124/mol.110.065250</pub-id><pub-id pub-id-type="pmid">20702762</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derosa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maffioli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Auraptene and its Role in Chronic Diseases</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>929</volume>, <fpage>399</fpage>&#8211;<lpage>407</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-41342-6_19</pub-id><pub-id pub-id-type="pmid">27771936</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eghbaliferiz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Farhadi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Majeed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Effects of Curcumin on Neurological Diseases: Focus on Astrocytes</article-title>. <source>Pharmacol. Rep.</source><volume>72</volume>, <fpage>769</fpage>&#8211;<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1007/s43440-020-00112-3</pub-id><pub-id pub-id-type="pmid">32458309</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>EghbaliFeriz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taleghani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tayarani-Najaran</surname><given-names>Z.</given-names></name></person-group> (<year>2018</year>). <article-title>Scutellaria: Debates on the Anticancer Property</article-title>. <source>Biomed. Pharmacother.</source><volume>105</volume>, <fpage>1299</fpage>&#8211;<lpage>1310</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.06.107</pub-id><pub-id pub-id-type="pmid">30021367</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epifano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Genovese</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>A. P. N.</given-names></name></person-group> (<year>2013</year>). <article-title>Auraptene and its Effects on the Re-emergence of Colon Cancer Stem Cells</article-title>. <source>Phytother. Res.</source><volume>27</volume> (<issue>5</issue>), <fpage>784</fpage>&#8211;<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.4773</pub-id><pub-id pub-id-type="pmid">22761031</pub-id><pub-id pub-id-type="pmcid">PMC3496036</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The Anticancer Properties of Tanshinones and the Pharmacological Effects of Their Active Ingredients</article-title>. <source>Front. Pharmacol.</source><volume>11</volume>, <fpage>193</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00193</pub-id><pub-id pub-id-type="pmid">32265690</pub-id><pub-id pub-id-type="pmcid">PMC7098175</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Hepatoprotection of Auraptene from Peels of Citrus Fruits against Thioacetamide-Induced Hepatic Fibrosis in Mice by Activating Farnesoid X Receptor</article-title>. <source>Food Funct.</source><volume>9</volume> (<issue>5</issue>), <fpage>2684</fpage>&#8211;<lpage>2694</lpage>. <pub-id pub-id-type="doi">10.1039/c8fo00107c</pub-id><pub-id pub-id-type="pmid">29721568</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sakata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kitaori</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oyama</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Suppression of Beta-Catenin Mutation by Dietary Exposure of Auraptene, a Citrus Antioxidant, in N,N-diethylnitrosamine-induced Hepatocellular Carcinomas in Rats</article-title>. <source>Oncol. Rep.</source><volume>14</volume> (<issue>2</issue>), <fpage>345</fpage>&#8211;<lpage>351</lpage>. <pub-id pub-id-type="doi">10.3892/or.14.2.345</pub-id><pub-id pub-id-type="pmid">16012713</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shin-ichiroh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sugie</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Citrus Auraptene Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in C57BL/KsJ-db/dbMice</article-title>. <source>Nutr. Cancer</source><volume>58</volume> (<issue>1</issue>), <fpage>75</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1080/01635580701308216</pub-id><pub-id pub-id-type="pmid">17571970</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jalilzadeh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Samadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dehghan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dadpour</surname><given-names>M. R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Novel Nano-Vehicle for Delivery and Efficiency of Anticancer Auraptene against colon Cancer Cells</article-title>. <source>Sci. Rep.</source><volume>10</volume> (<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-58527-0</pub-id><pub-id pub-id-type="pmid">32005894</pub-id><pub-id pub-id-type="pmcid">PMC6994674</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamialahmadi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alamolhodaei</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Avan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gholami</surname><given-names>L.</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title>Auraptene Inhibits Migration and Invasion of Cervical and Ovarian Cancer Cells by Repression of Matrix Metalloproteinasas 2 and 9 Activity</article-title>. <source>J. Pharmacopuncture.</source><volume>21</volume> (<issue>3</issue>), <fpage>177</fpage>&#8211;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.3831/KPI.2018.21.021</pub-id><pub-id pub-id-type="pmid">30283705</pub-id><pub-id pub-id-type="pmcid">PMC6168187</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Suppression of Mitochondrial Respiration with Auraptene Inhibits the Progression of Renal Cell Carcinoma: Involvement of HIF-1&#945; Degradation</article-title>. <source>Oncotarget</source><volume>6</volume> (<issue>35</issue>), <fpage>38127</fpage>&#8211;<lpage>38138</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.5511</pub-id><pub-id pub-id-type="pmid">26474388</pub-id><pub-id pub-id-type="pmcid">PMC4741988</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>D. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>M. H.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Apoptogenic Activity of Auraptene of Zanthoxylum Schinifolium toward Human Acute Leukemia Jurkat T Cells Is Associated with ER Stress-Mediated Caspase-8 Activation that Stimulates Mitochondria-dependent or -independent Caspase cascade</article-title>. <source>Carcinogenesis</source><volume>28</volume> (<issue>6</issue>), <fpage>1303</fpage>&#8211;<lpage>1313</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgm028</pub-id><pub-id pub-id-type="pmid">17301064</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>An Insight into the Role of Citrus Bioactives in Modulation of colon Cancer</article-title>. <source>J. Funct. Foods</source><volume>13</volume>, <fpage>239</fpage>&#8211;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2014.12.043</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawabata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ohigashi</surname><given-names>H.</given-names></name></person-group> (<year>2006a</year>). <article-title>Auraptene Decreases the Activity of Matrix Metalloproteinases in Dextran Sulfate Sodium-Induced Ulcerative Colitis in ICR Mice</article-title>. <source>Biosci. Biotechnol. Biochem.</source><volume>70</volume>, <fpage>3065</fpage>. <pub-id pub-id-type="doi">10.1271/bbb.60393</pub-id><pub-id pub-id-type="pmid">17151446</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawabata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ohigashi</surname><given-names>H.</given-names></name></person-group> (<year>2006b</year>). <article-title>Citrus Auraptene Targets Translation of MMP-7 (Matrilysin) via ERK1/2-dependent and mTOR-independent Mechanism</article-title>. <source>FEBS Lett.</source><volume>580</volume> (<issue>22</issue>), <fpage>5288</fpage>&#8211;<lpage>5294</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2006.08.072</pub-id><pub-id pub-id-type="pmid">16979634</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wanibuchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kikuzaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakatani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Imaoka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Funae</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Chemopreventive Effects of Coumaperine from Pepper on the Initiation Stage of Chemical Hepatocarcinogenesis in the Rat</article-title>. <source>Jpn. J. Cancer Res.</source><volume>91</volume> (<issue>7</issue>), <fpage>674</fpage>&#8211;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2000.tb00998.x</pub-id><pub-id pub-id-type="pmid">10920273</pub-id><pub-id pub-id-type="pmcid">PMC5926419</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleiner-Hancock</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Remeika</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>J. N.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Effects of ATRA Combined with Citrus and Ginger-Derived Compounds in Human SCC Xenografts</article-title>. <source>BMC Cancer</source><volume>10</volume> (<issue>1</issue>), <fpage>394</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-10-394</pub-id><pub-id pub-id-type="pmid">20659317</pub-id><pub-id pub-id-type="pmcid">PMC2916922</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Greer</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Abu-Rustum</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Apte</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>K. R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Cervical Cancer, Version 2.2015</article-title>. <source>J. Natl. Compr. Canc Netw.</source><volume>13</volume> (<issue>4</issue>), <fpage>395</fpage>&#8211;<lpage>404</lpage>. <pub-id pub-id-type="doi">10.6004/jnccn.2015.0055</pub-id><pub-id pub-id-type="pmid">25870376</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Curini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Epifano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maltese</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>S. P.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Dietary Administration with Prenyloxycoumarins, Auraptene and Collinin, Inhibits Colitis-Related colon Carcinogenesis in Mice</article-title>. <source>Int. J. Cancer</source><volume>118</volume> (<issue>12</issue>), <fpage>2936</fpage>&#8211;<lpage>2942</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.21719</pub-id><pub-id pub-id-type="pmid">16395701</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kleiner-Hancock</surname><given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>Effects of Auraptene on IGF-1 Stimulated Cell Cycle Progression in the Human Breast Cancer Cell Line, MCF-7</article-title>. <source>Int. J. Breast Cancer.</source><volume>2012</volume>, <fpage>502092</fpage>. <pub-id pub-id-type="doi">10.1155/2012/502092</pub-id><pub-id pub-id-type="pmid">23320178</pub-id><pub-id pub-id-type="pmcid">PMC3536038</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Windler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tubbs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B. D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Citrus Auraptene Suppresses Cyclin D1 and Significantly Delays N-Methyl Nitrosourea Induced Mammary Carcinogenesis in Female Sprague-Dawley Rats</article-title>. <source>BMC Cancer</source><volume>9</volume> (<issue>1</issue>), <fpage>259</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-9-259</pub-id><pub-id pub-id-type="pmid">19640308</pub-id><pub-id pub-id-type="pmcid">PMC2724550</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuki</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hosotani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohigashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Metabolism and Absorption of Auraptene (7-geranyloxylcoumarin) in Male SD Rats: Comparison with 7-ethoxycoumarin</article-title>. <source>Nutr. Cancer</source><volume>60</volume> (<issue>3</issue>), <fpage>368</fpage>&#8211;<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1080/01635580701745327</pub-id><pub-id pub-id-type="pmid">18444171</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.-I.</given-names></name><name name-style="western"><surname>Chitsazian-Yazdi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Auraptene Induces Apoptosis via Myeloid Cell Leukemia 1-Mediated Activation of Caspases in PC3 and DU145 Prostate Cancer Cells</article-title>. <source>Phytother. Res.</source><volume>31</volume> (<issue>6</issue>), <fpage>891</fpage>&#8211;<lpage>898</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.5810</pub-id><pub-id pub-id-type="pmid">28383142</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Si</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>A New Terpene Coumarin Microbial Transformed by Mucor Polymorphosporus Induces Apoptosis of Human Gastric Cancer Cell Line MGC-803</article-title>. <source>Arch. Pharm. Res.</source><volume>41</volume> (<issue>6</issue>), <fpage>646</fpage>&#8211;<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-018-1028-0</pub-id><pub-id pub-id-type="pmid">29619675</pub-id><pub-id pub-id-type="pmcid">PMC6028838</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maleki</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Bahrami</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Sadeghian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Discovering the Structure&#8211;Activity Relationships of Different O-Prenylated Coumarin Derivatives as Effective Anticancer Agents in Human Cervical Cancer Cells</article-title>. <source>Toxicol. Vitro.</source><volume>63</volume>, <fpage>104745</fpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2019.104745</pub-id><pub-id pub-id-type="pmid">31830504</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Auraptene, a Major Compound of Supercritical Fluid Extract of Phalsak (Citrus Hassaku Hort Ex Tanaka), Induces Apoptosis through the Suppression of mTOR Pathways in Human Gastric Cancer SNU-1 Cells</article-title>. <source>Evid. Based. Complement. Alternat. Med.</source><volume>2015</volume>, <fpage>402385</fpage>. <pub-id pub-id-type="doi">10.1155/2015/402385</pub-id><pub-id pub-id-type="pmid">26351512</pub-id><pub-id pub-id-type="pmcid">PMC4550746</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motlagh</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Gholami</surname><given-names>O.</given-names></name></person-group> (<year>2017</year>). <article-title>Comparison of Umbelliprenin and Auraptene in Cytotoxic Effects and Myeloid Cell Leukemia Type-1 (Mcl-1) Gene Expression</article-title>. <source>Indian J. Pharm. Sci.</source><volume>78</volume> (<issue>6</issue>), <fpage>827</fpage>&#8211;<lpage>833</lpage>. <pub-id pub-id-type="doi">10.4172/pharmaceutical-sciences.1000189</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moussavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>F.</given-names></name><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rassouli</surname><given-names>F. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Efficacy of Hyperthermia in Human colon Adenocarcinoma Cells Is Improved by Auraptene</article-title>. <source>Biochem. Cel Biol.</source><volume>96</volume> (<issue>1</issue>), <fpage>32</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1139/bcb-2017-0146</pub-id><pub-id pub-id-type="pmid">28915362</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moussavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rassouli</surname><given-names>F. B.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soleymanifard</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Synergy between Auraptene, Ionizing Radiation, and Anticancer Drugs in colon Adenocarcinoma Cells</article-title>. <source>Phytother. Res.</source><volume>31</volume> (<issue>9</issue>), <fpage>1369</fpage>&#8211;<lpage>1375</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.5863</pub-id><pub-id pub-id-type="pmid">28675489</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuki</surname><given-names>W.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yonei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ohto</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Auraptene, a Citrus Coumarin, Inhibits 12-0-Tetradecanoylphorbol-13-Acetate-Induced Tumor Promotion in ICR Mouse Skin, Possibly through Suppression of Superoxide Generation in Leukocytes</article-title>. <source>Jpn. J. Cancer Res.</source><volume>88</volume> (<issue>5</issue>), <fpage>443</fpage>&#8211;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.1997.tb00402.x</pub-id><pub-id pub-id-type="pmid">9247600</pub-id><pub-id pub-id-type="pmcid">PMC5921462</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Haga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuki</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>
<italic toggle="yes">In Vitro</italic> absorption and Metabolism of a Citrus Chemopreventive Agent, Auraptene, and its Modifying Effects on Xenobiotic Enzyme Activities in Mouse Livers</article-title>. <source>Nutr. Cancer</source><volume>36</volume> (<issue>2</issue>), <fpage>191</fpage>&#8211;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1207/s15327914nc3602_8</pub-id><pub-id pub-id-type="pmid">10890030</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohnishi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Asamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tujimura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hokaiwado</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Inhibition of Cell Proliferation by Nobiletin, a Dietary Phytochemical, Associated with Apoptosis and Characteristic Gene Expression, but Lack of Effect on Early Rat Hepatocarcinogenesis <italic toggle="yes">In Vivo</italic>
</article-title>. <source>Cancer Sci.</source><volume>95</volume> (<issue>12</issue>), <fpage>936</fpage>&#8211;<lpage>942</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb03180.x</pub-id><pub-id pub-id-type="pmid">15596041</pub-id><pub-id pub-id-type="pmcid">PMC11158043</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saboor-Maleki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rassouli</surname><given-names>F. B.</given-names></name><name name-style="western"><surname>Matin</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Auraptene Attenuates Malignant Properties of Esophageal Stem-like Cancer Cells</article-title>. <source>Technol. Cancer Res. Treat.</source><volume>16</volume> (<issue>4</issue>), <fpage>519</fpage>&#8211;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1177/1533034616650119</pub-id><pub-id pub-id-type="pmid">27207438</pub-id><pub-id pub-id-type="pmcid">PMC5616061</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hirose</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Dietary Supplementation of the Citrus Antioxidant Auraptene Inhibits N,N-Diethylnitrosamine-Induced Rat Hepatocarcinogenesis</article-title>. <source>Oncology</source><volume>66</volume> (<issue>3</issue>), <fpage>244</fpage>&#8211;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1159/000078001</pub-id><pub-id pub-id-type="pmid">15218316</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Afkhami-Poostchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soleymanifard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakhaei-Rad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Merajifar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Coadministration of Auraptene and Radiotherapy; a Novel Modality against colon Carcinoma Cells <italic toggle="yes">In Vitro</italic> and <italic toggle="yes">In Vivo</italic>
</article-title>. <source>Int. J. Radiat. Biol.</source><volume>96</volume>, <fpage>1051</fpage>&#8211;<lpage>1059</lpage>. <pub-id pub-id-type="doi">10.1080/09553002.2020.1770359</pub-id><pub-id pub-id-type="pmid">32412318</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekiguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Suppression of CD74 Expression and <italic toggle="yes">Helicobacter pylori</italic> Adhesion by Auraptene Targeting Serum Starvation-Activated ERK1/2 in NCI-N87 Gastric Carcinoma Cells</article-title>. <source>Biosci. Biotechnol. Biochem.</source><volume>74</volume>, <fpage>1018</fpage>&#8211;<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1271/bbb.90910</pub-id><pub-id pub-id-type="pmid">20460732</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekiguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takabayashi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>K.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Auraptene Attenuates Gastritis via Reduction ofHelicobacter pyloriColonization and Pro-inflammatory Mediator Production in C57BL/6 Mice</article-title>. <source>J. Med. Food</source><volume>15</volume> (<issue>7</issue>), <fpage>658</fpage>&#8211;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1089/jmf.2011.1844</pub-id><pub-id pub-id-type="pmid">22471969</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taleghani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eghbali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shokouhnam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Emami</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Farhadi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Asili</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Anti-Melanogenic Activities of Different Extracts from Pistacia Atlantica Subsp</article-title>. <source>Kurdica. Jundishapur J. Nat. Pharm. Prod.</source><volume>16</volume> (<issue>2</issue>), <fpage>1</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.5812/jjnpp.69844</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kakumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuki</surname><given-names>W.</given-names></name><etal/></person-group> (<year>1998a</year>). <article-title>Citrus Auraptene Exerts Dose-dependent Chemopreventive Activity in Rat Large Bowel Tumorigenesis: the Inhibition Correlates with Suppression of Cell Proliferation and Lipid Peroxidation and with Induction of Phase II Drug-Metabolizing Enzymes</article-title>. <source>Cancer Res.</source><volume>58</volume> (<issue>12</issue>), <fpage>2550</fpage>&#8211;<lpage>2556</lpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-9-259</pub-id><pub-id pub-id-type="pmid">9635577</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kagami</surname><given-names>S.</given-names></name><name name-style="western"><surname>El-Bayoumy</surname><given-names>K.</given-names></name></person-group> (<year>2000</year>). <article-title>Suppressing Effects of Dietary Supplementation of the Organoselenium 1,4-phenylenebis(methylene)selenocyanate and the Citrus Antioxidant Auraptene on Lung Metastasis of Melanoma Cells in Mice</article-title>. <source>Cancer Res.</source><volume>60</volume> (<issue>14</issue>), <fpage>3713</fpage>&#8211;<lpage>3716</lpage> . <pub-id pub-id-type="pmid">10919638</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Azevedo</surname><given-names>M. B. M.</given-names></name><name name-style="western"><surname>Dur&#225;n</surname><given-names>N.</given-names></name><name name-style="western"><surname>Alderete</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Epifano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Genovese</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Colorectal Cancer Chemoprevention by 2 &#946;-cyclodextrin Inclusion Compounds of Auraptene and 4&#8242;-geranyloxyferulic Acid</article-title>. <source>Int. J. Cancer</source><volume>126</volume> (<issue>4</issue>), <fpage>830</fpage>&#8211;<lpage>840</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.24833</pub-id><pub-id pub-id-type="pmid">19688830</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kakumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Makita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>H.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Citrus Auraptene Inhibits Chemically Induced Colonic Aberrant Crypt Foci in Male F344 Rats</article-title>. <source>Carcinogenesis</source><volume>18</volume> (<issue>11</issue>), <fpage>2155</fpage>&#8211;<lpage>2161</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/18.11.2155</pub-id><pub-id pub-id-type="pmid">9395216</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawabata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kakumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><etal/></person-group> (<year>1998b</year>). <article-title>Chemoprevention of 4-nitroquinoline 1-Oxide-Induced Oral Carcinogenesis by Citrus Auraptene in Rats</article-title>. <source>Carcinogenesis</source><volume>19</volume> (<issue>3</issue>), <fpage>425</fpage>&#8211;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/19.3.425</pub-id><pub-id pub-id-type="pmid">9525276</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yasui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishigamori-Suzuki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oyama</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>Citrus Compounds Inhibit Inflammation- and Obesity-Related Colon Carcinogenesis in Mice</article-title>. <source>Nutr. Cancer</source><volume>60</volume> (<issue>S1</issue>), <fpage>70</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1080/01635580802381253</pub-id><pub-id pub-id-type="pmid">19003583</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Asamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hokaiwado</surname><given-names>N.</given-names></name><name name-style="western"><surname>Seeni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Protective Effects of Citrus Nobiletin and Auraptene in Transgenic Rats Developing Adenocarcinoma of the Prostate (TRAP) and Human Prostate Carcinoma Cells</article-title>. <source>Cancer Sci.</source><volume>98</volume> (<issue>4</issue>), <fpage>471</fpage>&#8211;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2007.00417.x</pub-id><pub-id pub-id-type="pmid">17284254</pub-id><pub-id pub-id-type="pmcid">PMC11158555</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torre</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lortet-Tieulent</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Global Cancer Statistics, 2012</article-title>. <source>CA: A Cancer J. Clinicians</source><volume>65</volume> (<issue>2</issue>), <fpage>87</fpage>&#8211;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vakili</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iranshahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arab</surname><given-names>H.</given-names></name><name name-style="western"><surname>Riahi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roshan</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Safety Evaluation of Auraptene in Rats in Acute and Subacute Toxicity Studies</article-title>. <source>Regul. Toxicol. Pharmacol.</source><volume>91</volume>, <fpage>159</fpage>&#8211;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2017.10.025</pub-id><pub-id pub-id-type="pmid">29080847</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Hainaut</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gores</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Amadou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Plymoth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>L. R.</given-names></name></person-group> (<year>2019</year>). <article-title>A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source><volume>16</volume>, <fpage>589</fpage>&#8211;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1038/s41575-019-0186-y</pub-id><pub-id pub-id-type="pmid">31439937</pub-id><pub-id pub-id-type="pmcid">PMC6813818</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Rapid and Sensitive LC-MS/MS Method for the Determination of Auraptene in Rat Plasma and its Application in a Pharmacokinetic and Bioavailability Study in Rats</article-title>. <source>Genet. Mol. Res.</source><volume>15</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.4238/gmr.15028786</pub-id><pub-id pub-id-type="pmid">27420975</pub-id></mixed-citation></ref></ref-list><sec id="s9"><title>Glossary</title><def-list><def-item><term id="G1-fphar-2021-698352">ACAT:</term><def><p>cholesterol acyltransferase</p></def></def-item><def-item><term id="G2-fphar-2021-698352">ACF:</term><def><p>aberrant crypt foci</p></def></def-item><def-item><term id="G3-fphar-2021-698352">ALDH1:</term><def><p>aldehyde dehydrogenase 1</p></def></def-item><def-item><term id="G4-fphar-2021-698352">AOM:</term><def><p>azoxymethane</p></def></def-item><def-item><term id="G5-fphar-2021-698352">ATRA:</term><def><p>all-trans retinoic acid</p></def></def-item><def-item><term id="G6-fphar-2021-698352">AUR:</term><def><p>auraptene</p></def></def-item><def-item><term id="G7-fphar-2021-698352">BMI-1:</term><def><p>B cell-specific moloney murine leukemia virus integration site 1</p></def></def-item><def-item><term id="G8-fphar-2021-698352">CD44:</term><def><p>cluster of differentiation 44</p></def></def-item><def-item><term id="G9-fphar-2021-698352">COX-2:</term><def><p>cyclooxygenase-2</p></def></def-item><def-item><term id="G10-fphar-2021-698352">ERs:</term><def><p>estrogen receptors</p></def></def-item><def-item><term id="G11-fphar-2021-698352">ERK1/2:</term><def><p>extracellular signal-regulated kinase</p></def></def-item><def-item><term id="G12-fphar-2021-698352">ESCC:</term><def><p>esophageal squamous cell carcinoma</p></def></def-item><def-item><term id="G13-fphar-2021-698352">GATA6:</term><def><p>GATA binding protein 6</p></def></def-item><def-item><term id="G14-fphar-2021-698352">GST:</term><def><p>gluthathione S-transferase</p></def></def-item><def-item><term id="G15-fphar-2021-698352">HIF-1&#945;:</term><def><p>hypoxia-inducible factor 1&#945;</p></def></def-item><def-item><term id="G16-fphar-2021-698352">IGF-1:</term><def><p>insulin-like growth factor-1</p></def></def-item><def-item><term id="G17-fphar-2021-698352">iNOS:</term><def><p>inducible nitric oxide synthase</p></def></def-item><def-item><term id="G18-fphar-2021-698352">MMP9:</term><def><p>matrix metallopeptidase 9</p></def></def-item><def-item><term id="G19-fphar-2021-698352">MMP2:</term><def><p>matrix metallopeptidase 2</p></def></def-item><def-item><term id="G20-fphar-2021-698352">Mcl-1:</term><def><p>myeloid cell leukaemia Type-1</p></def></def-item><def-item><term id="G21-fphar-2021-698352">NF-&#954;B:</term><def><p>nuclear factor-kappaB, Stat3</p></def></def-item><def-item><term id="G22-fphar-2021-698352">NF-E2:</term><def><p>nuclear factor erythroid 2</p></def></def-item><def-item><term id="G23-fphar-2021-698352">4-NQO:</term><def><p>4-nitroquinoline 1-oxide</p></def></def-item><def-item><term id="G24-fphar-2021-698352">PARP:</term><def><p>poly (ADP-ribose) polymerase</p></def></def-item><def-item><term id="G25-fphar-2021-698352">PCNA:</term><def><p>proliferating cell nuclear antigen</p></def></def-item><def-item><term id="G26-fphar-2021-698352">PDT:</term><def><p>photodynamic therapy</p></def></def-item><def-item><term id="G27-fphar-2021-698352">QR:</term><def><p>quinone reductaseand</p></def></def-item><def-item><term id="G28-fphar-2021-698352">RCC:</term><def><p>renal cell carcinoma</p></def></def-item><def-item><term id="G29-fphar-2021-698352">SCC:</term><def><p>squamous cell carcinomas</p></def></def-item><def-item><term id="G30-fphar-2021-698352">TNF-&#945;:</term><def><p>tumor necrosis factor-a, signal transducer and activator of transcription 3</p></def></def-item><def-item><term id="G31-fphar-2021-698352">TPA:</term><def><p>tetradecanoylphorbol-13-acetate</p></def></def-item><def-item><term id="G32-fphar-2021-698352">TUNEL:</term><def><p>transferase dUTP nick end labeling</p></def></def-item><def-item><term id="G33-fphar-2021-698352">VEGFR-1:</term><def><p>Vascular endothelial groth factor</p></def></def-item></def-list></sec></back></article></pmc-articleset>